Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UPP1 | Q16831 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31575258 | 0.70 | UPP1 (0.49) | UPP1CA12CA9PDE3BPDE3A | |
| SCHEMBL2674746 | 0.65 | — | — | |
| SCHEMBL24195963 | 0.65 | MCL1 (0.41) | ALDH1A1 | |
| SCHEMBL2956418 | 0.62 | UPP1 (0.37) | UPP1PDE3BPDE3A | |
| SCHEMBL584505 | 0.61 | UPP1 (0.59) | UPP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL25426756 | 0.61 | ENPP3 (0.42) | CA12CA9PDE3BPDE3AALDH1A1 | |
| SCHEMBL1281155 | 0.61 | — | — | |
| SCHEMBL6516876 | 0.60 | UPP1 (0.57) | UPP1ALDH1A1 | |
| SCHEMBL10933269 | 0.59 | DAO (0.40) | UPP1ALDH1A1 | |
| SCHEMBL27891587 | 0.59 | L3MBTL1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | disclosed |
| EP-2512478-B1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-04-19 | — | — | EP | disclosed |
| US-9597326-B2 | Benzonapthyridine compositions and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-21 | — | — | US | disclosed |
| US-20160375132-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | disclosed |
| US-9408907-B2 | Homogenous suspension of immunopotentiating compounds and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-08-09 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| CN-102015651-B | Compounds and compositions as TLR activity modulators | IRM LLC | 2014-12-31 | — | — | CN | disclosed |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| EP-2440245-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | Novartis AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011130379-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011084549-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-07-14 | — | — | WO | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375132-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | CD14, ICOS, CD69 | UPP1 1429/4885CA12 2991/4885CA9 4709/4885 |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | LY96, TLR3, GABRA4 | UPP1 4160/4885CA12 1791/4885CA9 3147/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | UPP1 3787/4885CA12 3590/4885CA9 2637/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | UPP1 607/4885CA12 3836/4885CA9 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.